Stuttgart
30.10.26 | 16:31
0,653 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10. | Advicenne reports First Half financial results as of June 30, 2026, and updates on its activities | 2 | Euronext | ||
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 12.10. | Advicenne Extends Cash Runway To 2028 With €1 Million Bond Financing And Strong Product Sales | 2 | pulse2.com | ||
| 12.10. | Advicenne Extends Its Cash Runway to 2028 Through Bond Financing and Strong Operational Performance | 409 | Business Wire | €1 million in net cash proceeds received from the remaining tranche of the financing agreement signed with a fund managed by L1 Capital in June 2026. Financial runway extended to 2028,... ► Artikel lesen | |
| 17.09. | Advicenne Reports First Half Financial Results as of June 30, 2026, and Updates on Its Activities | 489 | Business Wire | Sibnayal end-market sales (Europe and Middle East) up 27% to €6.6 million, with royalties received increasing 45% to €0.54 million. Positive half-year net result of €4.6 million, compared... ► Artikel lesen | |
| 31.08. | Kurseinbruch bei Advicenne | 674 | Bernecker Börsenbriefe | Das französische Biopharma-Unternehmen hat den Zulassungsantrag bei der US-Gesundheitsbehörde FDA für das Medikament ADV7103 zur Behandlung der primären distalen renal-tubulären Azidose zurückgezogen.... ► Artikel lesen | |
| 31.08. | Advicenne decides to withdraw its ADV7103 New Drug Application in the USA | 516 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 20.07. | Advicenne Announces the Reimbursement of Sibnayal for the Treatment of dRTA in Spain | 460 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 16.07. | Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal and Likozam in France | 714 | Business Wire | The first half 2026 reported revenue is the first without the negative impact of early access rebates Reported revenue does not include royalties to be received from commercial partners... ► Artikel lesen | |
| 01.07. | Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal in the United Kingdom | 590 | Business Wire | Regulatory News:
Advicenne S.A. (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering... ► Artikel lesen | |
| 22.06. | Advicenne Secures Its Cash Runway to Q2 2027 through a Bond Financing of a Nominal Amount of up to €3.8 Million | 721 | Business Wire | The transaction reflects the commitment of key shareholders, such as Cemag Invest and Didier Laurens, Chairman and CEO, joined by Europe Offering and L1 Capital. Immediate funding of €1.4... ► Artikel lesen | |
| 01.06. | Advicenne Granted Reimbursement for Likozam in France and Sees Thereby Its Debt Reduced by Nearly €6 Million | 379 | Business Wire | Likozam will be reimbursed to patients starting June 12, 2026 Official reimbursement ends the "Early Access" clawback The price obtained offsets the discounts owed under the early... ► Artikel lesen | |
| 21.05. | Advicenne Announces Changes to Its Governance Following Its Annual General Meeting on May 21, 2026 | 558 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 -ALDVI), a pharmaceutical company specializing in the development and marketing of innovativetreatments for people suffering from... ► Artikel lesen | |
| 05.05. | Advicenne Announces the Opening of a Safeguard Proceedings to Restructure Its Financial Liabilities and Finalize the Extension of Its Cash Runway | 770 | Business Wire | A proactive initiative to restructure the Company's debt A protective framework that allows for the continuation of commercial, clinical, and regulatory activities, as well as discussions... ► Artikel lesen | |
| 24.04. | Advicenne 2025 Universal Registration Document Made Available | 497 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 26.03. | Advicenne Reports Its 2025 Annual Financial Results | 1.084 | Business Wire | Product sales up 18.7% to €5.8 million
European end-market sales of Sibnayal rose by more than 71% to nearly €11 million
Royalties doubled to over €1.1 million
Cash position... ► Artikel lesen | |
| 02.02. | Advicenne: Official Reimbursement of Sibnayal for the Treatment of dRTA in France | 936 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 27.01. | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in UAE | 562 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 22.01. | Advicenne: 2025 Full Year Sales | 667 | Business Wire | 2025 sales totaled €5.73m, up 18.4%
Sibnayal sales rose 36.6% to €3.01m
2025 Royalties are estimated at €1m, double the amount for 2024
End-markets estimated sales of Sibnayal... ► Artikel lesen | |
| 20.01. | Advicenne: 2026 Financial Calendar | 569 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 19.01. | Advicenne: FDA Has Accepted for Review the Marketing Authorization Application for Sibnayal in the United States for the Treatment of dRTA | 572 | Business Wire | The US regulatory agency has set the target date for the final approval decision, known as the PDUFA date, as of September 3rd, 2026.
Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 50,64 | +5,59 % | Bayer meldet positive Phase-III-Daten zu Darolutamid bei Prostatakrebs | Bayer hat mit seinem Krebsmedikament Darolutamid in einer Phase-III-Studie bei Prostatakrebspatienten mit hohem Rückfallrisiko den primären Endpunkt erreicht. In der DASL-HiCaP-Studie verringerte die... ► Artikel lesen | |
| PFIZER | 27,215 | +1,30 % | JEFFERIES stuft PFIZER INC auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Pfizer mit einem Kursziel von 36 US-Dollar auf "Buy" belassen. Akash Tewari bezieht sich in seiner am Montag vorliegenden... ► Artikel lesen | |
| ABBVIE | 265,40 | +1,49 % | Otsuka und AbbVie kaufen sich in die Psychedelika-Medizin ein: Was das für die Infrastruktur-Frage bedeutet | ||
| ELI LILLY | 1.272,80 | +3,45 % | KI-Blase vor dem Platzen?: Anleger wenden sich von KI-Aktien ab - diese Branche profitiert jetzt | © Foto: Midjourney (KI) - Midjourney (KI)Während KI-Aktien unter Druck geraten, gewinnen Gesundheitswerte an Attraktivität. Pharma- und Medizintechnikaktien könnten langfristig profitieren Enthaltene... ► Artikel lesen | |
| MERCK & CO | 133,22 | +1,26 % | 21 % Absturz: Daten-Leak löst Ausverkauf bei Moderna aus | © Foto: Jakub Porzycki - NurPhotoDie Moderna-Aktie bricht nach geleakten Studiendaten zu einem Krebsimpfstoff zweistellig ein. Dabei sind die Ergebnisse vielversprechend. Was steckt dahinter Enthaltene... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 56,06 | +1,91 % | 380-Millionen-Dollar-Deal geplatzt: Bristol Myers zieht Konsequenzen - Mesoblast meldet 44 Prozent Umsatzplus | ||
| INNOCAN PHARMA | 1,060 | -8,23 % | InnoCan Pharma: Umsatzsprung und frisches Geld stützen die Story | ||
| DOCMORRIS | 16,770 | -4,17 % | JEFFERIES stuft DocMorris auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat DocMorris nach Gesprächen mit dem Management der Online-Apotheke mit einem Kursziel von 11 Franken auf "Hold" belassen. Darin sei es um die... ► Artikel lesen | |
| INCYTE | 108,45 | +3,63 % | Incyte Posts Loss In Q3, But Revenue Rises; Lifts Sales Outlook | WASHINGTON (dpa-AFX) - Incyte Corp. (INCY), a biopharmaceutical company, Thursday reported a third-quarter loss compared with a profit a year earlier, primarily due to a one-time research and... ► Artikel lesen | |
| SINOPHARM | 1,835 | +1,58 % | SINOPHARM (01099): ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE THIRD QUARTER OF 2026 | ||
| HALEON | 3,866 | +0,86 % | Deutsche Bank upgrades Haleon to 'hold' from 'sell' | ||
| HAPPY BELLY FOOD GROUP | 0,910 | +1,11 % | Happy Belly Food Group Inc.: Happy Belly Food Group Announces the Grand Opening of Yolks Breakfast in Vaughan, Ontario | Toronto, Ontario--(Newsfile Corp. - October 30, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| MERCK KGAA | 151,35 | +0,70 % | BARCLAYS stuft MERCK KGAA auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Merck KGaA von 150 auf 160 Euro angehoben, aber die Einstufung auf "Equal Weight" belassen. Analyst Charles Pitman-King... ► Artikel lesen | |
| SANOFI | 79,85 | +4,61 % | Ihre wichtigsten Termine: Cameco, AbbVie, Chevron, BP, AstraZeneca & General Dynamics mit frischen Updates | © Foto: Andrew Milligan - PA WireGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte:... ► Artikel lesen | |
| NOVO NORDISK | 35,635 | +2,28 % | Pharmaaktien mit Zukunft - Bayer, BioNxt Solutions, Novo Nordisk füllen ihre Pipelines | Kein Pharmakonzern lebt ewig von seinen Bestsellern. Irgendwann läuft der Patentschutz aus, Nachahmer drängen in den Markt und die Margen schrumpfen. Wer dann keinen Nachschub hat, sitzt auf dem Trockenen.... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.